<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20241219051204&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20241219051204&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 19 Dec 2024 10:12:06 +0000</lastbuilddate>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39694037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth relies on efficient ATP synthesis, although the underlying mechanisms remain unclear. Here, we report that YTHDF2 facilitates energy supply and antigen escape in B cell malignancies, and its overexpression alone is sufficient to cause B cell transformation and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 12:S0092-8674(24)01324-2. doi: 10.1016/j.cell.2024.11.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth relies on efficient ATP synthesis, although the underlying mechanisms remain unclear. Here, we report that YTHDF2 facilitates energy supply and antigen escape in B cell malignancies, and its overexpression alone is sufficient to cause B cell transformation and tumorigenesis. Mechanistically, YTHDF2 functions as a dual reader where it stabilizes mRNAs as a 5-methylcytosine (m<sup>5</sup>C) reader via recruiting PABPC1, thereby enhancing their expression and ATP synthesis. Concomitantly, YTHDF2 also promotes immune evasion by destabilizing other mRNAs as an N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) reader. Small-molecule-mediated targeting of YTHDF2 suppresses aggressive B cell malignancies and sensitizes them to CAR-T cell therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39694037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39694037</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.007>10.1016/j.cell.2024.11.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39694037</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhenhua Chen</dc:creator>
<dc:creator>Chengwu Zeng</dc:creator>
<dc:creator>Lu Yang</dc:creator>
<dc:creator>Yuan Che</dc:creator>
<dc:creator>Meiling Chen</dc:creator>
<dc:creator>Lillian Sau</dc:creator>
<dc:creator>Bintao Wang</dc:creator>
<dc:creator>Keren Zhou</dc:creator>
<dc:creator>Yu Chen</dc:creator>
<dc:creator>Ying Qing</dc:creator>
<dc:creator>Chao Shen</dc:creator>
<dc:creator>Tingjian Zhang</dc:creator>
<dc:creator>Mark Wunderlich</dc:creator>
<dc:creator>Dong Wu</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Kitty Wang</dc:creator>
<dc:creator>Keith Leung</dc:creator>
<dc:creator>Miao Sun</dc:creator>
<dc:creator>Tingting Tang</dc:creator>
<dc:creator>Xin He</dc:creator>
<dc:creator>Lianjun Zhang</dc:creator>
<dc:creator>Srividya Swaminathan</dc:creator>
<dc:creator>James C Mulloy</dc:creator>
<dc:creator>Markus Müschen</dc:creator>
<dc:creator>Huilin Huang</dc:creator>
<dc:creator>Hengyou Weng</dc:creator>
<dc:creator>Gang Xiao</dc:creator>
<dc:creator>Xiaolan Deng</dc:creator>
<dc:creator>Jianjun Chen</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies</dc:title>
<dc:identifier>pmid:39694037</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.007</dc:identifier>
</item>
<item>
<title>Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693096/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this study, potassium nitrate did not improve aerobic capacity, total work, or quality of life in participants with HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4417. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Nitric oxide deficiency may contribute to exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). Prior pilot studies have shown improvements in exercise tolerance with single-dose and short-term inorganic nitrate administration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized double-blinded crossover trial was conducted at the University of Pennsylvania, the Philadelphia Veterans Affairs Medical Center, and Northwestern University between October 2016 and July 2022. Participants included patients with symptomatic (New York Heart Association class II/III) HFpEF who had objective signs of elevated left ventricular filling pressures. Image quantification, physiological data modeling and biochemical measurements, unblinding, and statistical analyses were completed in 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Potassium nitrate (KNO3) (6 mmol 3 times daily) vs equimolar doses of potassium chloride (KCl) for 6 weeks, each with a 1-week washout in between.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The coprimary end points included peak oxygen uptake and total work performed during a maximal effort incremental cardiopulmonary exercise test. Secondary end points included the exercise systemic vasodilatory reserve (ie, reduction in systemic vascular resistance with exercise) and quality of life assessed using the Kansas City Cardiomyopathy Questionnaire.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Eighty-four participants were enrolled. Median age was 68 years and 58 participants were women (69.0%). Most participants had NYHA class II disease (69%) with a mean 6-minute walk distance of 335.5 (SD, 97.3) m. Seventy-seven participants received the KNO3 intervention and 74 received the KCl intervention. KNO3 increased trough levels of serum nitric oxide metabolites after 6 weeks (KNO3, 418.4 [SD, 26.9] uM vs KCl, 40.1 [SD, 28.3] uM; P &lt; .001). KNO3 did not improve peak oxygen uptake (KNO3, 10.23 [SD, 0.43] mL/min/kg vs KCl, 10.17 [SD, 0.43] mL/min/kg; P = .73) or total work performed (KNO3, 25.9 [SD, 3.65] kilojoules vs KCl, 23.63 [SD, 3.63] kilojoules; P = .29). KNO3 nitrate did not improve the vasodilatory reserve or quality of life, though it was well-tolerated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, potassium nitrate did not improve aerobic capacity, total work, or quality of life in participants with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02840799.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693096/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39693096</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4417>10.1001/jamacardio.2024.4417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693096</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Payman Zamani</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Jordana B Cohen</dc:creator>
<dc:creator>Manyun Zhao</dc:creator>
<dc:creator>Wei Yang</dc:creator>
<dc:creator>Jessica L Afable</dc:creator>
<dc:creator>Maria Caturla</dc:creator>
<dc:creator>Hannah Maynard</dc:creator>
<dc:creator>Bianca Pourmussa</dc:creator>
<dc:creator>Cassandra Demastus</dc:creator>
<dc:creator>Ipsita Mohanty</dc:creator>
<dc:creator>Michelle Menon Miyake</dc:creator>
<dc:creator>Srinath Adusumalli</dc:creator>
<dc:creator>Kenneth B Margulies</dc:creator>
<dc:creator>Stuart B Prenner</dc:creator>
<dc:creator>David C Poole</dc:creator>
<dc:creator>Neil Wilson</dc:creator>
<dc:creator>Ravinder Reddy</dc:creator>
<dc:creator>Raymond R Townsend</dc:creator>
<dc:creator>Harry Ischiropoulos</dc:creator>
<dc:creator>Thomas P Cappola</dc:creator>
<dc:creator>Julio A Chirinos</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39693096</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4417</dc:identifier>
</item>
<item>
<title>Chest Pain in a Middle-Aged Man</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693088/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4440. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693088/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39693088</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4440>10.1001/jamacardio.2024.4440</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693088</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Qinghua Chang</dc:creator>
<dc:creator>Zhaolong Xu</dc:creator>
<dc:creator>Renguang Liu</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Chest Pain in a Middle-Aged Man</dc:title>
<dc:identifier>pmid:39693088</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4440</dc:identifier>
</item>
<item>
<title>Trajectory of Cardiovascular Health Across Childhood and Adolescence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study provides insight into the trajectory of CVH early in life, which may contribute to CVH disparities in adulthood, and identified modifiable health behaviors for focused prevention efforts to optimize CVH in early life.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The American Heart Association put forth the Life's Essential 8 construct to assess cardiovascular health (CVH) based on 8 behavioral and health factors. Few studies have characterized the natural history of CVH in early life or identified its sociodemographic determinants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize CVH trajectories across childhood and adolescence and identify associations with sociodemographic variables.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This study used data from the Project Viva prebirth cohort, an ongoing prospective prebirth cohort study conducted in a large multispecialty group practice in eastern Massachusetts among women who were pregnant and enrolled from April 1999 to November 2002. Participant inclusion required 3 or more CVH metrics in early childhood (median [range] age, 3.2 [2.8-6.2] years) or 4 metrics or more in midchildhood (median [range] age, 7.7 [6.6-10.9] years), early adolescence (median [range] age, 13.0 [11.9-16.6] years), or late adolescence (median [range] age, 17.5 [15.4-20.1] years). Of 2218 live births in the original cohort, 1523 were included in the present analysis. Data were analyzed from June to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Child sex, race, and ethnicity; maternal education; and household income.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: CVH score (0-100 points) from early childhood to late adolescence, calculated as the unweighted average of all available CVH metrics at each life stage.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1523 children, 782 (51.4%) were male; 53 (3.5%) were non-Hispanic Asian, 231 (15.2%) were non-Hispanic Black, 988 (65.0%) were non-Hispanic White, and 175 (11.5%) were non-Hispanic other. The mean (SD) CVH score was 82.6 (8.6) in early childhood, 84.1 (8.3) in midchildhood, 82.0 (9.8) in early adolescence, and 73.8 (11.5) in late adolescence. The estimated mean (SD) age of inflection when CVH score declined was 10.1 (0.7) years for male children and 10.0 (0.6) years for female children; the decline in CVH was associated with health behaviors rather than health factors. Male children (vs female children) had faster CVH score gain before the inflection (β, 0.79 points/year; 95% CI, 0.67 to 0.91) and faster CVH score decline after the inflection (β, -0.33 points/year; 95% CI, -0.44 to -0.22). Non-Hispanic Black children (β, 0.32 years; 95% CI, 0.20 to 0.43) and children of other non-Hispanic races (β, 0.16 years; 95% CI, 0.05 to 0.28) children had later timing of inflection compared with non-Hispanic White children. Children of mothers without (vs with) a college degree or with household income $70 000 per year or less (vs greater than $70 000/year) exhibited lower CVH trajectory throughout childhood. Children of mothers with some college education (vs a college degree) had later timing of inflection (β, 0.16 years; 95% CI, 0.07 to 0.26) and slower CVH score gain before the inflection (β, -0.24 points/year; 95% CI, -0.40 to -0.08).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides insight into the trajectory of CVH early in life, which may contribute to CVH disparities in adulthood, and identified modifiable health behaviors for focused prevention efforts to optimize CVH in early life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39693062</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4022>10.1001/jamacardio.2024.4022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693062</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Izzuddin M Aris</dc:creator>
<dc:creator>Sheryl L Rifas-Shiman</dc:creator>
<dc:creator>Wei Perng</dc:creator>
<dc:creator>Li Yi</dc:creator>
<dc:creator>Sarah D de Ferranti</dc:creator>
<dc:creator>Marie-France Hivert</dc:creator>
<dc:creator>Emily Oken</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Trajectory of Cardiovascular Health Across Childhood and Adolescence</dc:title>
<dc:identifier>pmid:39693062</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4022</dc:identifier>
</item>
<item>
<title>Preventing Declines in Cardiovascular Health From Childhood: Never Too Early for Heart Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39693059</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4019>10.1001/jamacardio.2024.4019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693059</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Natalie A Cameron</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Preventing Declines in Cardiovascular Health From Childhood: Never Too Early for Heart Health</dc:title>
<dc:identifier>pmid:39693059</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4019</dc:identifier>
</item>
<item>
<title>2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39692645/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 11:S0735-1097(24)10301-4. doi: 10.1016/j.jacc.2024.10.100. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39692645/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39692645</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.100>10.1016/j.jacc.2024.10.100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39692645</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Writing Committee</dc:creator>
<dc:creator>Michael T Spooner</dc:creator>
<dc:creator>Steven R Messé</dc:creator>
<dc:creator>Seemant Chaturvedi</dc:creator>
<dc:creator>Monika M Do</dc:creator>
<dc:creator>Ty J Gluckman</dc:creator>
<dc:creator>Janet K Han</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Sherry J Saxonhouse</dc:creator>
<dc:creator>Newton B Wiggins</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:39692645</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.100</dc:identifier>
</item>
<item>
<title>ACKR1&lt;sup>;hi&lt;/sup>;ECs Promote Aortic Dissection Through Adjusting Macrophage Behavior</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39692014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study reveals how endothelial cells exhibiting high ACKR1 expression modulate macrophage migration and proinflammatory polarization through the ACKR1/NF-κB/SPP1 signaling pathway, a crucial mechanism in TAAD progression. Targeting ACKR1 through both functional and pharmacological approaches effectively suppressed TAAD progression and extended survival in TAAD mice, offering promising new intervention strategies for clinical evaluation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 18. doi: 10.1161/CIRCRESAHA.124.325458. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Type A aortic dissection (TAAD) is a life-threatening condition characterized by complex pathophysiology, in which macrophages play a critical but not yet fully understood role. This study focused on the role of endothelial cells with elevated expression of ACKR1 (atypical chemokine receptor 1) and their interaction with proinflammatory macrophages in TAAD development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Single-cell transcriptomic analysis of human aortic tissues revealed increased populations of endothelial cells exhibiting high ACKR1 expression and proinflammatory macrophages in TAAD samples. Both clinical and animal studies revealed that ACKR1 expression levels were strongly linked to TAAD severity. Gain- and loss-of-function studies demonstrated that ACKR1 promotes TAAD progression. Specific knockdown of ACKR1 in endothelial cells suppressed the NF-κB (nuclear factor-κB) signaling pathway and SPP1 (secreted phosphoprotein 1) expression, leading to reduced macrophage migration and proinflammatory polarization, which subsequently inhibited TAAD development. Conversely, ACKR1 overexpression accelerated TAAD progression. Notably, molecular docking and comprehensive evaluation identified amikacin as a potential novel modulator of ACKR1. Extensive in vitro and in vivo studies demonstrated that amikacin can regulate macrophage behavior through the ACKR1/NF-κB/SPP1 signaling pathway, thereby attenuating TAAD progression and improving survival rates in TAAD mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study reveals how endothelial cells exhibiting high ACKR1 expression modulate macrophage migration and proinflammatory polarization through the ACKR1/NF-κB/SPP1 signaling pathway, a crucial mechanism in TAAD progression. Targeting ACKR1 through both functional and pharmacological approaches effectively suppressed TAAD progression and extended survival in TAAD mice, offering promising new intervention strategies for clinical evaluation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39692014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39692014</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325458>10.1161/CIRCRESAHA.124.325458</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39692014</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yayu Wang</dc:creator>
<dc:creator>Xiong Jia</dc:creator>
<dc:creator>Yifei Zhang</dc:creator>
<dc:creator>Bin Zhang</dc:creator>
<dc:creator>Yazhe Zhou</dc:creator>
<dc:creator>Xiaoru Li</dc:creator>
<dc:creator>Xiaoying Zhu</dc:creator>
<dc:creator>Jinquan Xia</dc:creator>
<dc:creator>Jun Ren</dc:creator>
<dc:creator>Chang Zou</dc:creator>
<dc:creator>Qijun Zheng</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>ACKR1&lt;sup>;hi&lt;/sup>;ECs Promote Aortic Dissection Through Adjusting Macrophage Behavior</dc:title>
<dc:identifier>pmid:39692014</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325458</dc:identifier>
</item>
<item>
<title>Follistatin From hiPSC-Cardiomyocytes Promotes Myocyte Proliferation in Pigs With Postinfarction LV Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39692006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ^(KO/OE)hiPSC-CM spheroids significantly improved cardiac function and reduced infarct size in pig hearts after ischemia/reperfusion injury by secreting follistatin, which upregulated HIPPO/YAP signaling and proliferation in endogenous pig cardiomyocytes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 18. doi: 10.1161/CIRCRESAHA.124.325562. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: When human induced pluripotent stem cells (hiPSCs) that CCND2-OE (overexpressed cyclin-D2) were differentiated into cardiomyocytes (<sup>CCND2-OE</sup>hiPSC-CMs) and administered to the infarcted hearts of immunodeficient mice, the cells proliferated after administration and repopulated >;50% of the scar. Here, we knocked out human leukocyte antigen class I and class II expression in <sup>CCND2-OE</sup>hiPSC-CMs (<sup>KO/OE</sup>hiPSC-CMs) to reduce the cells' immunogenicity and then assessed the therapeutic efficacy of <sup>KO/OE</sup>hiPSC-CMs for the treatment of myocardial infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: <sup>KO/OE</sup>hiPSC-CM and wild-type hiPSC-CM (<sup>WT</sup>hiPSC-CM) spheroids were differentiated in shaking flasks, purified, characterized, and intramyocardially injected into pigs after ischemia/reperfusion injury; control animals were injected with basal medium. Cardiac function was evaluated via cardiac magnetic resonance imaging, and cardiomyocyte proliferation was assessed via immunostaining and single-nucleus RNA sequencing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Measurements of cardiac function and scar size were significantly better in pigs treated with <sup>KO/OE</sup>hiPSC-CM spheroids than in animals treated with medium or <sup>WT</sup>hiPSC-CM spheroids. <sup>KO/OE</sup>hiPSC-CMs were detected for just 1 week after administration, but assessments of cell cycle activity and proliferation were significantly higher in the endogenous pig cardiomyocytes of the hearts from the <sup>KO/OE</sup>hiPSC-CM spheroid group than in those from the other 2 groups. Single-nucleus RNA-sequencing analysis identified a cluster of proliferating cardiomyocytes that was significantly more prevalent in the <sup>KO/OE</sup>hiPSC-CM spheroid-treated hearts (3.65%) than in the hearts from the medium (0.89%) or <sup>WT</sup>hiPSC-CM spheroid (1.33%) groups at week 1. YAP (Yes-associated protein) protein levels and nuclear localization were also significantly upregulated in pig cardiomyocytes after treatment with <sup>KO/OE</sup>hiPSC-CM spheroids. Follistatin, which interacts with the HIPPO/YAP pathway, was significantly more abundant in the medium from <sup>KO/OE</sup>hiPSC-CM spheroids than <sup>WT</sup>hiPSC-CM spheroids (30.29±2.39 versus 16.62±0.83 ng/mL, <i>P</i>=0.0056). Treatment with follistatin increased <sup>WT</sup>hiPSC-CM cell counts by 28.3% over 16 days in culture and promoted cardiomyocyte proliferation in the infarcted hearts of adult mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: <sup>KO/OE</sup>hiPSC-CM spheroids significantly improved cardiac function and reduced infarct size in pig hearts after ischemia/reperfusion injury by secreting follistatin, which upregulated HIPPO/YAP signaling and proliferation in endogenous pig cardiomyocytes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39692006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39692006</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325562>10.1161/CIRCRESAHA.124.325562</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39692006</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuhua Wei</dc:creator>
<dc:creator>Gregory Walcott</dc:creator>
<dc:creator>Thanh Nguyen</dc:creator>
<dc:creator>Xiaoxiao Geng</dc:creator>
<dc:creator>Bijay Guragain</dc:creator>
<dc:creator>Hanyu Zhang</dc:creator>
<dc:creator>Akazha Green</dc:creator>
<dc:creator>Manuel Rosa-Garrido</dc:creator>
<dc:creator>Jack M Rogers</dc:creator>
<dc:creator>Daniel J Garry</dc:creator>
<dc:creator>Lei Ye</dc:creator>
<dc:creator>Jianyi Zhang</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Follistatin From hiPSC-Cardiomyocytes Promotes Myocyte Proliferation in Pigs With Postinfarction LV Remodeling</dc:title>
<dc:identifier>pmid:39692006</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325562</dc:identifier>
</item>
<item>
<title>SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39690446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 17. doi: 10.1161/CIRCRESAHA.124.324708. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39690446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39690446</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324708>10.1161/CIRCRESAHA.124.324708</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39690446</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Maryna V Basalay</dc:creator>
<dc:creator>Alla Korsak</dc:creator>
<dc:creator>Zhenhe He</dc:creator>
<dc:creator>Alexander V Gourine</dc:creator>
<dc:creator>Sean M Davidson</dc:creator>
<dc:creator>Derek M Yellon</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity</dc:title>
<dc:identifier>pmid:39690446</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324708</dc:identifier>
</item>
<item>
<title>Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39689849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Light-to-moderate wine consumption, measured through an objective biomarker (tartaric acid), was prospectively associated with lower CVD rate in a Mediterranean population at high cardiovascular risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 18:ehae804. doi: 10.1093/eurheartj/ehae804. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Moderate wine consumption has been associated with lower cardiovascular disease (CVD) risk in older populations. However, wine consumption information through self-reports is prone to measurement errors inherent to subjective assessments. The aim of this study was to evaluate the association between urinary tartaric acid, an objective biomarker of wine consumption, and the rate of a composite clinical CVD event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A case-cohort nested study was designed within the PREDIMED trial with 1232 participants: 685 incident cases of CVD and a random subcohort of 625 participants (including 78 overlapping cases). Wine consumption was registered using validated food frequency questionnaires. Liquid chromatography-tandem mass spectrometry was used to measure urinary tartaric acid at baseline and after one year of intervention. Weighted Cox regression models were used to estimate hazard ratios (HRs) of CVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Tartaric acid was correlated with self-reported wine consumption at baseline [r = 0.46 (95% CI 0.41; 0.50)]. Five categories of post hoc urinary tartaric acid excretion were used for better representation of risk patterns. Concentrations of 3-12 and 12-35 μg/mL, which reflect ∼3-12 and 12-35 glasses/month of wine, were associated with lower CVD risk [HR 0.62 (95% CI 0.38; 1.00), P = .050 and HR 0.50 (95% CI 0.27; 0.95), P = .035, respectively]. Less significant associations between self-reported wine consumption and CVD risk were observed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Light-to-moderate wine consumption, measured through an objective biomarker (tartaric acid), was prospectively associated with lower CVD rate in a Mediterranean population at high cardiovascular risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39689849/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39689849</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae804>10.1093/eurheartj/ehae804</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39689849</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Inés Domínguez-López</dc:creator>
<dc:creator>Rosa M Lamuela-Raventós</dc:creator>
<dc:creator>Cristina Razquin</dc:creator>
<dc:creator>Camila Arancibia-Riveros</dc:creator>
<dc:creator>Polina Galkina</dc:creator>
<dc:creator>Jordi Salas-Salvadó</dc:creator>
<dc:creator>Ángel M Alonso-Gómez</dc:creator>
<dc:creator>Montserrat Fitó</dc:creator>
<dc:creator>Miquel Fiol</dc:creator>
<dc:creator>José Lapetra</dc:creator>
<dc:creator>Enrique Gómez-Gracia</dc:creator>
<dc:creator>José V Sorlí</dc:creator>
<dc:creator>Miguel Ruiz-Canela</dc:creator>
<dc:creator>Olga Castañer</dc:creator>
<dc:creator>Liming Liang</dc:creator>
<dc:creator>Lluis Serra-Majem</dc:creator>
<dc:creator>Frank B Hu</dc:creator>
<dc:creator>Emilio Ros</dc:creator>
<dc:creator>Miguel Ángel Martínez-González</dc:creator>
<dc:creator>Ramon Estruch</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial</dc:title>
<dc:identifier>pmid:39689849</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae804</dc:identifier>
</item>
<item>
<title>Wine consumption and cardiovascular health: the unresolved French paradox and the promise of objective biomarkers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39689843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 18:ehae726. doi: 10.1093/eurheartj/ehae726. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39689843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39689843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae726>10.1093/eurheartj/ehae726</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39689843</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Giovanni de Gaetano</dc:creator>
<dc:creator>Simona Costanzo</dc:creator>
<dc:creator>Augusto Di Castelnuovo</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Wine consumption and cardiovascular health: the unresolved French paradox and the promise of objective biomarkers</dc:title>
<dc:identifier>pmid:39689843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae726</dc:identifier>
</item>
<item>
<title>Lifetime risk of lower extremity peripheral arterial disease: a Danish nationwide longitudinal study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39688733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: More than one in 10 Danish individuals are diagnosed with symptomatic PAD during their lifetime. Peripheral arterial disease diagnosis is associated with high morbidity and mortality at 1 and 5 years.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 17:ehae867. doi: 10.1093/eurheartj/ehae867. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Lower extremity peripheral arterial disease (PAD) presents a substantial disease burden, yet lifetime estimates remain scant. This nationwide study quantified the lifetime risk of PAD and its clinical outcomes in Denmark.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cohort study included 4 275 631 individuals in Denmark aged 40-99 years between 1998 and 2018. We estimated the lifetime risk using a modified survival analysis method, considering death as a competing risk event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median 15.5-year follow-up, 151 846 individuals were diagnosed with PAD (median age at diagnosis 71.5 years, interquartile range 63.1-79.2). The overall lifetime risk of PAD from age 40 was 11.6% (95% confidence interval 11.6%-11.7%), decreasing from 12.9% in 1998-2002 to 10.7% in 2013-18. Males had a higher lifetime risk than females (12.8% vs. 10.5%). Socioeconomic disparities were evident, with higher risks for those with lower educational levels (risk difference 3.4%, 95% confidence interval 3.2%-3.6%) and lower income (risk difference 0.4%, 95% confidence interval 0.2%-0.5%). One year after PAD diagnosis, 21.4% had undergone lower limb revascularization, 8.0% had experienced a major amputation, and 16.2% had died. At 5 years, the corresponding proportions were 26.4%, 10.8%, and 40.8%, respectively. The risk of lower limb revascularization showed little variation by sex and socioeconomic status, whereas there was a strong socioeconomic gradient for major amputation and all-cause death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: More than one in 10 Danish individuals are diagnosed with symptomatic PAD during their lifetime. Peripheral arterial disease diagnosis is associated with high morbidity and mortality at 1 and 5 years.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39688733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39688733</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae867>10.1093/eurheartj/ehae867</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39688733</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Mette Søgaard</dc:creator>
<dc:creator>Christian-Alexander Behrendt</dc:creator>
<dc:creator>Nikolaj Eldrup</dc:creator>
<dc:creator>Flemming Skjøth</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lifetime risk of lower extremity peripheral arterial disease: a Danish nationwide longitudinal study</dc:title>
<dc:identifier>pmid:39688733</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae867</dc:identifier>
</item>
<item>
<title>Diffusion tensor imaging to assess myocardial microstructure after infarction by magnetic resonance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39688390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 17:ehae806. doi: 10.1093/eurheartj/ehae806. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39688390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39688390</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae806>10.1093/eurheartj/ehae806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39688390</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Erica Dall'Armellina</dc:creator>
<dc:creator>Sven Plein</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Diffusion tensor imaging to assess myocardial microstructure after infarction by magnetic resonance</dc:title>
<dc:identifier>pmid:39688390</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae806</dc:identifier>
</item>
<item>
<title>METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39687989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study revealed a novel mechanism by which mtDNA 6mA orchestrated mitochondrial function-related gene expression in macrophages, thereby promoting atherosclerosis. Through various experimental techniques, such as gene manipulation, pharmacological inhibition, and proteolysis targeting chimera, this study demonstrated that mtDNA 6mA and its specific enzyme METTL4 hold potential as therapeutic targets for atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17. doi: 10.1161/CIRCULATIONAHA.124.069574. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mitochondrial dysfunction is a key factor in the development of atherogenesis. METTL4 (methyltransferase-like protein 4) mediates N6- methyldeoxyadenosine (6mA) of mammalian mitochondrial DNA (mtDNA). However, the role of METTL4-mediated mitoepigenetic regulation in atherosclerosis is still unknown. This study aims to investigate the potential involvement of METTL4 in atherosclerosis, explore the underlying mechanism, and develop targeted strategies for treating atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Expression levels of mtDNA 6mA and METTL4 were determined in atherosclerotic lesions. We explored the mechanism of METTL4 involvement in atherosclerosis using <i>Mettl4</i><sup><i>Mac</i></sup><sup><i>-KO</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> and <i>Mettl4</i><sup><i>MUT</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> mice and cell models, as well as bone marrow transplantation. Natural compound libraries were screened to identify potent METTL4 antagonists. In addition, bioinspired proteolysis targeting chimera technology targeting macrophages within plaques was used to increase the efficacy of the METTL4 antagonist.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The expression levels of mtDNA 6mA and METTL4 were significantly increased in plaque macrophages. <i>Mettl4</i><sup><i>Mac-KO</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> mice displayed suppressed mtDNA 6mA levels and atherosclerotic progression, which were reversed by METTL4 restoration through bone marrow transplantation (n=6). Mechanistically, elevated METTL4 expression reduces MT-ATP6 expression by suppressing its transcription, thereby impairing the activity of mitochondrial respiration chain complex V. This disruption leads to the accumulation of excess protons in the mitochondrial intermembrane space, causing mitochondrial dysfunction. Consequently, mtDNA is released into the cytoplasm, ultimately triggering inflammasome activation. All results were reversed by the mutation in the METTL4 methyltransferase active site. <i>Mettl4</i><sup><i>MUT</i></sup>-<i>Apoe</i><sup><i>-/</i>-</sup> mice showed suppressed mtDNA 6mA levels and atherosclerotic progression and repaired mitochondrial function of macrophage, which were reversed by METTL4 restoration through bone marrow transplantation (n=6). Pemetrexed was identified as the first METTL4 antagonist to effectively alleviate atherosclerotic progression. Furthermore, we generated a proteolysis targeting chimera drug based on pemetrexed that specifically targeted METTL4 in macrophages within plaques, showing a promising therapeutic effect on atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study revealed a novel mechanism by which mtDNA 6mA orchestrated mitochondrial function-related gene expression in macrophages, thereby promoting atherosclerosis. Through various experimental techniques, such as gene manipulation, pharmacological inhibition, and proteolysis targeting chimera, this study demonstrated that mtDNA 6mA and its specific enzyme METTL4 hold potential as therapeutic targets for atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39687989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39687989</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069574>10.1161/CIRCULATIONAHA.124.069574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39687989</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Longbin Zheng</dc:creator>
<dc:creator>Xiang Chen</dc:creator>
<dc:creator>Xian He</dc:creator>
<dc:creator>Huiyuan Wei</dc:creator>
<dc:creator>Xinyu Li</dc:creator>
<dc:creator>Yongkang Tan</dc:creator>
<dc:creator>Jiao Min</dc:creator>
<dc:creator>Minghong Chen</dc:creator>
<dc:creator>Yunjia Zhang</dc:creator>
<dc:creator>Mengdie Dong</dc:creator>
<dc:creator>Quanwen Yin</dc:creator>
<dc:creator>Mengdie Xue</dc:creator>
<dc:creator>Lulu Zhang</dc:creator>
<dc:creator>Da Huo</dc:creator>
<dc:creator>Hong Jiang</dc:creator>
<dc:creator>Tingyou Li</dc:creator>
<dc:creator>Fei Li</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Xuesong Li</dc:creator>
<dc:creator>Hongshan Chen</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis</dc:title>
<dc:identifier>pmid:39687989</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069574</dc:identifier>
</item>
<item>
<title>Targeting macrophage-fibroblast interactions in the failing heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39681733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Dec 16. doi: 10.1038/s41569-024-01112-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39681733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39681733</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01112-z>10.1038/s41569-024-01112-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39681733</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Nikolaos G Frangogiannis</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Targeting macrophage-fibroblast interactions in the failing heart</dc:title>
<dc:identifier>pmid:39681733</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01112-z</dc:identifier>
</item>
<item>
<title>Future of Antihypertensive Therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):1987-1989. doi: 10.1161/CIRCULATIONAHA.124.072417. Epub 2024 Dec 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39680660</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072417>10.1161/CIRCULATIONAHA.124.072417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680660</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Luke J Laffin</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Future of Antihypertensive Therapies</dc:title>
<dc:identifier>pmid:39680660</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072417</dc:identifier>
</item>
<item>
<title>ASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680659/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):2070-2072. doi: 10.1161/CIRCULATIONAHA.124.071071. Epub 2024 Dec 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39680659</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071071>10.1161/CIRCULATIONAHA.124.071071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680659</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jelena Pavlović</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>M Kamran Ikram</dc:creator>
<dc:creator>M Arfan Ikram</dc:creator>
<dc:creator>Daniel Bos</dc:creator>
<dc:creator>Maarten J G Leening</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>ASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individuals</dc:title>
<dc:identifier>pmid:39680659</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071071</dc:identifier>
</item>
<item>
<title>Letter by Wang and Huang Regarding Article, "Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):e688. doi: 10.1161/CIRCULATIONAHA.124.071181. Epub 2024 Dec 16.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39680658</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071181>10.1161/CIRCULATIONAHA.124.071181</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680658</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Hai-Yan Wang</dc:creator>
<dc:creator>Feng Huang</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Wang and Huang Regarding Article, "Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism"</dc:title>
<dc:identifier>pmid:39680658</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071181</dc:identifier>
</item>
<item>
<title>Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist and share pathophysiological mechanisms. The proportion of patients with AS and CAD requiring revascularization varies widely because of uncertainty about best clinical practices. Although combined surgical aortic valve replacement and coronary artery bypass grafting has been the standard of care, management options in patients with AS and CAD requiring revascularization have expanded with the advent of transcatheter...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 17;150(25):2046-2069. doi: 10.1161/CIRCULATIONAHA.124.070502. Epub 2024 Dec 16.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist and share pathophysiological mechanisms. The proportion of patients with AS and CAD requiring revascularization varies widely because of uncertainty about best clinical practices. Although combined surgical aortic valve replacement and coronary artery bypass grafting has been the standard of care, management options in patients with AS and CAD requiring revascularization have expanded with the advent of transcatheter aortic valve replacement (TAVR). Potential alternative treatment pathways include revascularization before TAVR, concomitant TAVR and percutaneous coronary intervention, percutaneous coronary intervention after TAVR and deferred percutaneous coronary intervention or hybrid procedures. Selection depends on underlying disease severity, antithrombotic treatment strategies, clinical presentation, and symptom evolution after TAVR. In patients undergoing surgical aortic valve replacement, the addition of coronary artery bypass grafting has been associated with improved long-term mortality, especially if CAD is complex. although it is associated with higher periprocedural risk. The therapeutic impact of percutaneous coronary intervention in patients with TAVR is less well-established. The multitude of clinical permutations and remaining uncertainties do not support a uniform treatment strategy for patients with AS and CAD. Therefore, to provide the best possible care for each individual patient, heart teams need to be familiar with the available data on AS and CAD. Herein, we provide an in-depth review of the evidence supporting the decision-making process between transcatheter and surgical approaches and the key elements of treatment selection in patients with AS and CAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39680657</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070502>10.1161/CIRCULATIONAHA.124.070502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680657</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Daijiro Tomii</dc:creator>
<dc:creator>Thomas Pilgrim</dc:creator>
<dc:creator>Michael A Borger</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:creator>Jonas Lanz</dc:creator>
<dc:creator>David Reineke</dc:creator>
<dc:creator>Matthias Siepe</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management</dc:title>
<dc:identifier>pmid:39680657</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070502</dc:identifier>
</item>
<item>
<title>Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39680373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 16:ehae624. doi: 10.1093/eurheartj/ehae624. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39680373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39680373</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae624>10.1093/eurheartj/ehae624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39680373</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Lloyd E Butel-Simoes</dc:creator>
<dc:creator>Doan T M Ngo</dc:creator>
<dc:creator>Aaron L Sverdlov</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score</dc:title>
<dc:identifier>pmid:39680373</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae624</dc:identifier>
</item>
<item>
<title>ET-3/ETBR Mediates Na&lt;sup>;+&lt;/sup>;-Activated Immune Signaling and Kidney Lymphatic Dynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39676651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241219051204&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings reveal a novel mechanism linking the isolevuglandin-mediated ET-3/ETBR axis with LECs and infiltrating dendritic cells. ET-3/ETBR signaling in lymphatic vessel dynamics is a novel pathogenic component and a possible therapeutic target in kidney disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 16. doi: 10.1161/CIRCRESAHA.124.324890. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lymphatic collecting vessels in the kidney are critical in clearing interstitial fluid, macromolecules, and infiltrating immune cells. Dysfunction of the lymphatic vessels can disrupt this process and exacerbate injury-associated inflammation in many disease conditions. We previously found that sodium accumulates within the kidney interstitium during proteinuric kidney injury and elevated sodium environments stimulate isolevuglandin production in antigen-presenting cells, stimulating T cells, and modulating inflammatory responses. In the present study, we investigated whether proteinuric injury increases production of isolevuglandin-adduct formation in antigen-presenting cells, their effects on lymphatic endothelial cells (LECs), and the role of the ET-3 (endothelin-3)/ETBR (endothelin type B receptor) on lymphatic vessel function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used a mouse model of nephrotoxin-induced proteinuric injury to show that proteinuric injury expanded the kidney lymphatic network and to immunophenotype the infiltrating immune cells. To determine mechanisms, we analyzed the interaction of migratory immune cells and LECs using an in vitro transwell migration assay, bulk RNA sequencing, and flow cytometric analysis. To determine the effect of ET-3/ETBR axis on lymphatic vessel contractility, we analyzed microdissected lymphangions utilizing a vessel perfusion chamber.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that animals with proteinuric injury have increased kidney lymphangiogenesis, isolevuglandin-producing dendritic cells, and IFN (interferon)-γ-producing CD4+T cells. The sodium avid environment present in kidney injury enhances the interaction between LECs and migratory antigen-presenting cells and LEC production of isolevuglandin-adducts. Elevated sodium environment-induced isolevuglandin-adduct formation facilitates the ET-3/ETBR communication between LECs and dendritic cells. In addition, the ET-3/ETBR axis modulates lymphatic collecting vessel pumping dynamics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings reveal a novel mechanism linking the isolevuglandin-mediated ET-3/ETBR axis with LECs and infiltrating dendritic cells. ET-3/ETBR signaling in lymphatic vessel dynamics is a novel pathogenic component and a possible therapeutic target in kidney disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39676651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241219051204&v=2.18.0.post9+e462414">39676651</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324890>10.1161/CIRCRESAHA.124.324890</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39676651</guid>
<pubDate>Mon, 16 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Ashley L Mutchler</dc:creator>
<dc:creator>Jianyong Zhong</dc:creator>
<dc:creator>Hai-Chun Yang</dc:creator>
<dc:creator>Shilin Zhao</dc:creator>
<dc:creator>Rachelle Crescenzi</dc:creator>
<dc:creator>Shannon Taylor</dc:creator>
<dc:creator>Roy L Rao</dc:creator>
<dc:creator>Elaine L Shelton</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:creator>Valentina Kon</dc:creator>
<dc:date>2024-12-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>ET-3/ETBR Mediates Na&lt;sup>;+&lt;/sup>;-Activated Immune Signaling and Kidney Lymphatic Dynamics</dc:title>
<dc:identifier>pmid:39676651</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324890</dc:identifier>
</item>





























</channel>
</rss>